<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Barthel A</dc:creator>
  <dc:creator>Benker G</dc:creator>
  <dc:creator>Berens K</dc:creator>
  <dc:creator>Diederich S</dc:creator>
  <dc:creator>Manfras B</dc:creator>
  <dc:creator>Gruber M</dc:creator>
  <dc:creator>Kanczkowski W</dc:creator>
  <dc:creator>Kline G</dc:creator>
  <dc:creator>Kamvissi-Lorenz V</dc:creator>
  <dc:creator>Hahner S</dc:creator>
  <dc:creator>Beuschlein F</dc:creator>
  <dc:creator>Brennand A</dc:creator>
  <dc:creator>Boehm BO</dc:creator>
  <dc:creator>Torpy DJ</dc:creator>
  <dc:creator>Bornstein SR</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Addison's disease - the traditional term for primary adrenal insufficiency (PAI) - is defined as the clinical manifestation of chronic glucocorticoid- and/or mineralocorticoid deficiency due to failure of the adrenal cortex which may result in an adrenal crisis with potentially life-threatening consequences. Even though efficient and safe pharmaceutical preparations for the substitution of endogenous gluco- and mineralocorticoids are established in therapy, the mortality in patients with PAI is still increased and the health-related quality of life (HRQoL) is often reduced.PAI is a rare disease but recent data report an increasing prevalence. In addition to the common "classical" causes of PAI like autoimmune, infectious, neoplastic and genetic disorders, other iatrogenic conditions - mostly pharmacological side effects (e. g., adrenal haemorrhage associated with anticoagulants, drugs affecting glucocorticoid synthesis, action or metabolism and some of the novel anti-cancer checkpoint inhibitors) are contributing factors to this phenomenon.Due to the rarity of the disease and often non-specific symptoms at least in the early stages, PAI is frequently not considered resulting in a delayed diagnosis. Successful therapy is mainly based on adequate patient education as a cornerstone in the prevention and management of adrenal crisis. A focus of current research is in the development of pharmacokinetically optimized glucocorticoid preparations as well as regenerative therapies.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/215765</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1055/a-0804-2715</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30562824</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Addison Disease</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Humans</dc:subject>
  <dc:title xmlns:ns3="xml" ns3:lang="en">An Update on Addison's Disease.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
